Meningococcal (group B) multicomponent recombinant adsorbed vaccine

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meningitis, Meningococcal, Serogroup B

Conditions

Meningitis, Meningococcal, Serogroup B

Trial Timeline

Dec 1, 2014 โ†’ Apr 1, 2015

About Meningococcal (group B) multicomponent recombinant adsorbed vaccine

Meningococcal (group B) multicomponent recombinant adsorbed vaccine is a phase 3 stage product being developed by Novartis for Meningitis, Meningococcal, Serogroup B. The current trial status is completed. This product is registered under clinical trial identifier NCT02305446. Target conditions include Meningitis, Meningococcal, Serogroup B.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02305446Phase 3Completed

Competing Products

20 competing products in Meningitis, Meningococcal, Serogroup B

See all competitors
ProductCompanyStageHype Score
RotaTeqยฎ + NeisVac-CยฎMerckPhase 3
77
DaptomycinMerckPre-clinical
23
Meningococcal ACWY conjugate vaccineNovartisPhase 3
77
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
85
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
77
Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and MenveoNovartisPhase 3
77
Meningococcal ACWY conjugate vaccineNovartisPhase 3
77
MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + VaricellaNovartisPhase 2
52
Hib-CRM197 + Hib-TTNovartisPhase 3
77
Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate VaccineNovartisPhase 3
77
MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvantedNovartisPhase 2
52
meningococcal B vaccine & meningococcal ACYW conjugate vaccineNovartisPhase 2
52
Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosineNovartisPhase 2
52
4CMenBNovartisApproved
85
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccineNovartisPhase 3
77
MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose)NovartisPhase 3
77
MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A VirusNovartisPhase 3
77
Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years)NovartisPhase 3
77
Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyreticNovartisPhase 2
52
Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) + Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) + Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) + Infanrix Hexa + Menjugate + PrevenarNovartisPhase 3
77